Edarbi is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone.
Results from clinical studies revealed that Edarbi was more effective in lowering 24-hour blood pressure compared to two other FDA-approved hypertension drugs, Diovan (valsartan) and Benicar (olmesartan).
Edarbi tablets will be available in 80mg and 40mg doses, with the recommended dosage being 80mg once daily.
The 40mg dose will be indicated for patients who are treated with high-dose diuretics taken to lower salt in the body.